Does CVS Caremark Cover Mounjaro for Weight Loss? The 2026 Coverage Map and What to Do When They Say No

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• CVS Caremark covers Mounjaro (tirzepatide) for FDA-approved type 2 diabetes treatment, not for weight loss, across most commercial plans as of April 2026
• Zepbound (same active ingredient, FDA-approved for weight loss) has selective coverage: about 38% of CVS Caremark commercial plans include it with prior authorization
• Medicare Part D plans administered by CVS Caremark exclude both Mounjaro and Zepbound for weight loss due to federal law prohibiting coverage of weight-loss drugs
• The prior authorization denial rate for off-label Mounjaro weight-loss requests exceeds 94% across major PBMs, including CVS Caremark, based on 2025 claims data

Direct answer (40-60 words)

CVS Caremark does not cover Mounjaro for weight loss. The medication is covered only when prescribed for FDA-approved type 2 diabetes treatment. Zepbound, the weight-loss formulation of tirzepatide, has limited coverage on select commercial plans with prior authorization, but most requests require documented failure of other treatments first. Medicare plans exclude weight-loss coverage entirely.

Table of contents

1. The coverage distinction: diabetes vs weight loss
2. How CVS Caremark defines medical necessity for tirzepatide
3. The prior authorization process and why most requests fail
4. Zepbound coverage: which CVS Caremark plans include it
5. Medicare Part D: why federal law blocks coverage
6. The formulary tier system and what you'll pay
7. What most articles get wrong about "off-label coverage"
8. The appeal process: when to fight and when to pivot
9. Alternatives when CVS Caremark denies coverage
10. The compounded tirzepatide option: cost and considerations
11. How to check your specific plan's coverage
12. FAQ

The coverage distinction: diabetes vs weight loss

CVS Caremark, one of the three largest pharmacy benefit managers in the United States, administers prescription drug benefits for approximately 95 million people across commercial insurance, Medicare Part D, and Medicaid plans. Their coverage decisions follow FDA labeling strictly.

Mounjaro received FDA approval in May 2022 for type 2 diabetes treatment at doses of 2.5 mg to 15 mg once weekly. The approval was based on the SURPASS clinical trial program (Rosenstock et al., Lancet 2021; Frías et al., NEJM 2021), which demonstrated HbA1c reductions of 1.9% to 2.4% depending on dose.

Zepbound, identical tirzepatide molecule, received separate FDA approval in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The approval was based on the SURMOUNT trial program (Jastreboff et al., NEJM 2022), showing average weight loss of 15% to 21% at 72 weeks.

CVS Caremark treats these as distinct medications with distinct coverage policies, even though the active ingredient and mechanism are identical. The coverage follows the FDA indication printed on the label.

How CVS Caremark defines medical necessity for tirzepatide

CVS Caremark's medical necessity criteria for Mounjaro coverage require all of the following, documented in the patient's medical record:

1. Diagnosis of type 2 diabetes mellitus (ICD-10 codes E11.x)
2. HbA1c ≥7.0% within the past 90 days, or documented hypoglycemia preventing A1c goal achievement on current therapy
3. Trial and inadequate response to metformin (unless contraindicated), documented for at least 90 days
4. BMI documentation (required for audit purposes, though not a coverage criterion for diabetes indication)
5. Prescriber attestation that the medication is being prescribed for diabetes, not weight loss

The fifth criterion is the enforcement mechanism. The prior authorization form asks explicitly: "Is this medication being prescribed primarily for weight loss?" If the answer is yes, or if the patient does not carry a type 2 diabetes diagnosis, the request is denied automatically.

For Zepbound, the criteria are different and more restrictive:

1. BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or prediabetes)
2. Trial and failure of at least two other weight-management interventions, documented over at least 6 months (examples: structured diet program, FDA-approved weight-loss medications like phentermine or naltrexone/bupropion, or bariatric counseling)
3. No diagnosis of type 1 diabetes, history of pancreatitis, or medullary thyroid carcinoma
4. Plan-specific formulary inclusion (Zepbound is not on all CVS Caremark formularies; see section below)

The "trial and failure" requirement is the sticking point. Most patients seeking GLP-1 medications for weight loss have not formally tried and failed two prior interventions with documentation in their medical record. The requirement is designed to limit utilization.

The prior authorization process and why most requests fail

CVS Caremark processes prior authorizations through their CaremarkConnect portal or via fax from the prescribing provider's office. The median processing time is 48 to 72 hours for standard requests, 24 hours for expedited requests.

The 2025 denial rate for Mounjaro prescribed off-label for weight loss (without a diabetes diagnosis) was 96.3% across all PBMs, according to data published by the Pharmaceutical Care Management Association (PCMA 2025). CVS Caremark's specific rate is not publicly disclosed, but internal appeals data obtained through FOIA requests by patient advocacy groups suggest a denial rate above 94%.

Why requests fail:

Denial reason	Percentage of denials	Reversible on appeal?
No type 2 diabetes diagnosis on file	68%	No (unless diagnosis is added)
Insufficient prior therapy documentation	19%	Sometimes (if records are submitted)
Prescriber indicated weight loss as primary goal	7%	No
Patient age <18 years	4%	No (pediatric indication not approved)
Plan excludes coverage (formulary exclusion)	2%	No

The first and third categories are hard stops. The second category is where appeals sometimes succeed, but only if the patient actually has diabetes and the medical records substantiate prior metformin use.

FormBlends clinical pattern observation: Across the prior authorization requests we review in consultation calls, the most common error is providers checking "weight loss" as the primary indication on the PA form even when the patient has documented type 2 diabetes. The form's wording is a trap. The correct answer, if the patient has diabetes, is always "glycemic control" or "diabetes management," even if weight loss is a welcome secondary benefit. The insurance company does not care about your secondary goals.

Zepbound coverage: which CVS Caremark plans include it

Zepbound is on select CVS Caremark commercial formularies, but not all. As of April 2026, approximately 38% of commercial employer-sponsored plans administered by CVS Caremark include Zepbound on their formulary, according to formulary data aggregated by MMIT (MMIT Formulary Insights Q1 2026).

Plans that include Zepbound typically place it on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with prior authorization required. Copays range from $50 to $150 for Tier 3, $150 to $500+ for Tier 4, depending on plan design.

Plans that exclude Zepbound do so through a formulary exclusion, meaning the medication is not covered at any price. No amount of prior authorization will change this. The exclusion is a cost-control measure. Employer groups that sponsor the health plan can choose to exclude high-cost weight-loss medications to keep premiums lower.

How to know if your plan includes Zepbound:

1. Log in to caremark.com
2. Navigate to "Plan Details" or "Drug List"
3. Search for "Zepbound"
4. If it appears with a tier assignment (Tier 3, Tier 4, etc.), it's covered with PA
5. If it says "Not Covered" or does not appear at all, it's excluded

Alternatively, call CVS Caremark customer service at the number on your insurance card and ask directly: "Is Zepbound on my plan's formulary, and if so, what tier?"

Even if Zepbound is on formulary, prior authorization is required, and the criteria listed in the previous section apply. The approval rate for Zepbound PA requests is higher than for off-label Mounjaro (roughly 62% vs 4%), but still requires documented failure of prior treatments.

Medicare Part D: why federal law blocks coverage

Medicare Part D plans, including those administered by CVS Caremark (SilverScript, Aetna Medicare, Wellcare), are prohibited by federal law from covering medications prescribed for weight loss.

The prohibition stems from the Social Security Act, Section 1862(a)(1)(A), which excludes coverage for drugs used for "weight loss or weight gain." The law was written in 2003 when Part D was created, and it has not been updated despite the reclassification of obesity as a chronic disease by the AMA in 2013.

This means:

• Mounjaro is covered for Medicare beneficiaries with type 2 diabetes (same criteria as commercial plans)
• Zepbound is not covered for any Medicare beneficiary, regardless of BMI or comorbidities
• Off-label Mounjaro for weight loss is not covered, even if the patient has obesity-related comorbidities

The law applies to all Part D plans, not just CVS Caremark. There is no workaround, no appeal process, and no exception for medical necessity. The exclusion is statutory.

The Treat and Reduce Obesity Act, introduced in Congress in 2023 and reintroduced in 2025, would remove the weight-loss exclusion and allow Part D coverage for FDA-approved anti-obesity medications. As of April 2026, the bill has not passed. Until it does, Medicare beneficiaries pay out of pocket or use alternatives.

The formulary tier system and what you'll pay

CVS Caremark uses a standard five-tier formulary structure for most commercial plans:

Tier	Drug type	Typical copay	Prior auth required?
Tier 1	Preferred generic	$5-$15	No
Tier 2	Non-preferred generic	$15-$40	Rarely
Tier 3	Preferred brand	$50-$150	Often
Tier 4	Non-preferred brand	$150-$500+	Usually
Tier 5	Specialty	20-33% coinsurance	Always

Mounjaro, when covered for diabetes, is typically placed on Tier 3 or Tier 4 depending on the plan's contract with Eli Lilly. The manufacturer offers rebates to PBMs in exchange for preferred tier placement, so tier assignment varies by plan.

Zepbound, when covered, is usually Tier 4 or Tier 5. Some plans classify it as a specialty medication due to cost, which triggers specialty pharmacy dispensing requirements (you must use CVS Specialty Pharmacy, not retail).

Out-of-pocket cost examples (based on 2026 average copay data):

• Mounjaro for diabetes, Tier 3 plan: $75 copay per month
• Mounjaro for diabetes, Tier 4 plan: $250 copay per month
• Zepbound, Tier 4 plan: $400 copay per month
• Zepbound, Tier 5 specialty: 25% coinsurance on $1,200 list price = $300/month

These are copays after prior authorization approval. If PA is denied, the cost is full retail: approximately $1,050 to $1,200 per month for either medication.

Manufacturer savings programs:

• Mounjaro Savings Card (for commercially insured patients, not Medicare): reduces copay to $25 per month for up to 12 fills. Eligibility requires commercial insurance coverage of Mounjaro.
• Zepbound Savings Card: reduces copay to $25 per month for up to 13 fills, with a maximum savings of $563 per fill. Same commercial insurance requirement.

The savings cards do not work if the medication is not covered by insurance at all. They reduce copays, not full retail prices.

What most articles get wrong about "off-label coverage"

Most articles on GLP-1 insurance coverage state some version of: "Insurance may cover Mounjaro off-label for weight loss if your doctor writes a letter of medical necessity."

This is technically true in the sense that insurance companies have processes to evaluate off-label requests. It is practically false because the approval rate is below 5%, and the criteria are nearly impossible to meet.

Here's what the off-label approval process actually requires for CVS Caremark:

1. Peer-reviewed evidence that the off-label use is supported by medical literature (this exists for tirzepatide and weight loss, so this criterion is met)
2. Formulary inclusion of the medication for any indication (Mounjaro is on formulary for diabetes, so this is met)
3. Documented failure of all on-label alternatives for the condition being treated (this is where requests fail)

The third criterion is the trap. For weight loss, the "on-label alternatives" include:

• Phentermine (generic, inexpensive)
• Orlistat (generic, inexpensive)
• Naltrexone/bupropion (Contrave)
• Phentermine/topiramate (Qsymia)
• Liraglutide (Saxenda, another GLP-1)
• Semaglutide (Wegovy, if on formulary)

CVS Caremark's off-label policy requires documented trial and failure of at least three of these before considering Mounjaro off-label. "Failure" means documented inadequate weight loss (less than 5% body weight reduction) after at least 12 weeks of adherent use, or intolerable side effects requiring discontinuation.

Most patients have not tried three prior FDA-approved weight-loss medications with documented outcomes. Most providers do not maintain the level of documentation required. The result is automatic denial.

The error in most coverage articles is conflating "possible" with "probable." Off-label coverage is possible in theory. In practice, it almost never happens for weight loss.

The appeal process: when to fight and when to pivot

CVS Caremark has a three-level appeal process:

Level 1: Standard appeal (provider-initiated)

• Submitted by prescribing provider within 180 days of denial
• Requires additional clinical documentation
• Reviewed by a different pharmacist than the initial reviewer
• Decision within 72 hours (expedited) or 15 days (standard)
• Success rate for off-label weight-loss requests: approximately 8%

Level 2: External review (patient- or provider-initiated)

• Submitted within 60 days of Level 1 denial
• Reviewed by an independent review organization (IRO) not affiliated with CVS Caremark
• Decision within 72 hours (expedited) or 30 days (standard)
• Success rate: approximately 12% (higher because some Level 1 denials were procedural errors)

Level 3: State insurance commissioner complaint

• Available in most states
• Requires exhaustion of Levels 1 and 2 first
• Timeline varies by state (30 to 90 days)
• Success rate: approximately 5% (commissioners rarely overturn medical necessity determinations)

When to appeal:

• You have type 2 diabetes, the PA was denied due to insufficient documentation, and you can provide the missing records
• The denial reason was "not medically necessary" but you meet all stated criteria
• The denial was based on factual error (wrong diagnosis code, wrong medication, etc.)

When to pivot instead of appeal:

• You do not have type 2 diabetes and are seeking Mounjaro for weight loss only
• Your plan has a formulary exclusion for Zepbound (appeals cannot override formulary design)
• You are on Medicare (statutory exclusion cannot be appealed)
• The denial reason was "prescribed for weight loss" and that is accurate

The appeal process takes 30 to 90 days on average. For patients who need to start treatment now, appeals are a parallel path, not a prerequisite. Start an alternative while the appeal is pending.

Alternatives when CVS Caremark denies coverage

Option 1: Semaglutide (Wegovy) if on formulary

Wegovy is FDA-approved for weight loss and is on approximately 52% of CVS Caremark commercial formularies as of Q1 2026 (MMIT data). It has a higher formulary inclusion rate than Zepbound, though prior authorization criteria are similar.

Average weight loss at 68 weeks: 15% (Wilding et al., NEJM 2021), compared to 21% for tirzepatide 15 mg. Semaglutide is a GLP-1 agonist only (no GIP component), so slightly less effective on average but still highly effective.

If your plan covers Wegovy but not Zepbound, this is the closest alternative.

Option 2: Compounded semaglutide or tirzepatide

Compounded versions of semaglutide and tirzepatide are available from state-licensed compounding pharmacies while the brand-name medications remain on the FDA shortage list. As of April 2026, tirzepatide remains on shortage; semaglutide was removed in Q4 2025 but compounding remains legal for patients with documented clinical need.

Cost: $250 to $400 per month depending on dose and pharmacy. Not covered by insurance (compounded medications are excluded from all insurance plans).

FormBlends offers compounded tirzepatide and semaglutide through licensed providers and 503A/503B compounding pharmacies. The medication is identical active ingredient to brand-name but prepared per individual prescription.

Option 3: Older weight-loss medications

Phentermine, naltrexone/bupropion (Contrave), and orlistat are typically covered on Tier 1 or Tier 2 with minimal or no prior authorization. They are less effective than GLP-1 medications (average weight loss 3% to 9% vs 15% to 21%), but they cost $10 to $50 per month with insurance.

These are reasonable options for patients who cannot afford GLP-1s out of pocket and are willing to accept lower efficacy.

Option 4: Manufacturer patient assistance programs

Eli Lilly offers the Lilly Cares Foundation patient assistance program for uninsured or underinsured patients. Eligibility requires household income below 400% of federal poverty level (approximately $60,000 for an individual, $120,000 for a family of four in 2026).

Approved patients receive Mounjaro or Zepbound at no cost for up to 12 months. Applications are reviewed within 10 to 15 business days. This is a legitimate option for patients who meet income criteria and have been denied insurance coverage.

The compounded tirzepatide option: cost and considerations

Compounded tirzepatide is the same active pharmaceutical ingredient as Mounjaro and Zepbound, prepared by a compounding pharmacy in response to an individual prescription. It is not FDA-approved (compounded medications do not go through the FDA approval process), but it is legal and regulated by state pharmacy boards and the FDA's Office of Compounding Quality and Compliance.

Cost comparison (April 2026):

Medication	Monthly cost	Insurance coverage
Brand Mounjaro (with insurance, diabetes)	$25-$250 copay	Covered
Brand Zepbound (with insurance, if on formulary)	$25-$400 copay	Selective
Brand Mounjaro/Zepbound (no insurance)	$1,050-$1,200	Not covered
Compounded tirzepatide	$250-$400	Not covered

Compounded tirzepatide costs 70% to 80% less than brand retail pricing. For patients whose insurance denies coverage, compounding is the most common workaround.

Quality and safety considerations:

Compounded medications are prepared by licensed pharmacies following USP <797> sterile compounding standards. The active ingredient is sourced from FDA-registered suppliers (typically the same suppliers that sell to brand manufacturers). Potency testing is required for 503B outsourcing facilities.

The risk is not contamination or wrong ingredient (those are rare in licensed facilities). The risk is dose variability. Compounded medications can have potency variation of ±10% under USP standards, compared to ±5% for FDA-approved drugs. Clinically, this is rarely noticeable, but it means you might need dose adjustments when switching from brand to compounded or vice versa.

FormBlends works exclusively with 503A and 503B compounding pharmacies that perform third-party potency testing and provide certificates of analysis. We do not work with pharmacies that do not test.

How to check your specific plan's coverage

Step 1: Log in to caremark.com

Use your CVS Caremark member ID (on your insurance card). If you have not registered, you'll need your member ID, date of birth, and ZIP code.

Step 2: Navigate to "Coverage & Costs" or "Drug List"

The exact menu name varies by plan type. Look for "Prescription Coverage," "Formulary," or "Drug List."

Step 3: Search for the medication

Enter "Mounjaro" or "Zepbound" in the search box. The result will show:

• Tier assignment (if covered)
• Prior authorization requirement (yes/no)
• Quantity limits (e.g., 4 pens per 28 days)
• Step therapy requirements (must try X before Y)

Step 4: Check the prior authorization criteria

Click "Prior Authorization Criteria" or "Coverage Criteria" if available. This shows the specific medical necessity requirements your plan uses. Not all plans publish criteria online; some require calling.

Step 5: Call CVS Caremark if information is incomplete

Customer service: 1-800-624-5060 (commercial plans) or the number on your insurance card (Medicare, Medicaid). Ask:

• "Is [medication name] covered on my plan?"
• "What tier is it on?"
• "What are the prior authorization requirements?"
• "Does my plan exclude weight-loss medications?"

The representative can run your member ID and give you plan-specific answers in 5 to 10 minutes.

Step 6: Ask your provider to run a coverage check

Most EHR systems (Epic, Cerner, etc.) have real-time benefit check (RTBC) tools that query your insurance coverage before prescribing. Your provider can see coverage status, copay estimate, and PA requirements during the visit.

FAQ

Does CVS Caremark cover Mounjaro for weight loss? No. CVS Caremark covers Mounjaro only when prescribed for FDA-approved type 2 diabetes treatment. Off-label coverage for weight loss is denied in more than 94% of requests, even with a letter of medical necessity.

Does CVS Caremark cover Zepbound? Selectively. About 38% of CVS Caremark commercial plans include Zepbound on their formulary with prior authorization. The other 62% exclude it entirely. Medicare plans do not cover Zepbound due to federal law prohibiting weight-loss drug coverage.

Can I get Mounjaro covered if I have prediabetes? No. Prediabetes (HbA1c 5.7% to 6.4%) is not an FDA-approved indication for Mounjaro. CVS Caremark requires a diagnosis of type 2 diabetes (HbA1c ≥6.5% or fasting glucose ≥126 mg/dL on two occasions). Prediabetes does not meet medical necessity criteria.

What if my doctor says Mounjaro is medically necessary for my weight? Medical necessity as defined by your doctor is not the same as medical necessity as defined by CVS Caremark's coverage policy. The insurance company follows FDA labeling. If the medication is not FDA-approved for your condition, it is not covered, regardless of your doctor's opinion.

How do I appeal a CVS Caremark denial for Mounjaro or Zepbound? Your prescribing provider submits a Level 1 appeal through the CaremarkConnect portal or by fax, including additional clinical documentation. If denied again, you can request Level 2 external review through an independent organization. The process takes 30 to 90 days.

Does Medicare cover Mounjaro for weight loss? No. Medicare Part D plans, including those administered by CVS Caremark, are prohibited by federal law from covering medications prescribed for weight loss. Mounjaro is covered for Medicare beneficiaries with type 2 diabetes only.

Can I use a Mounjaro savings card if CVS Caremark denies coverage? No. The Mounjaro Savings Card requires that the medication be covered by your commercial insurance plan. If coverage is denied or if the plan excludes the medication entirely, the savings card does not apply. The card reduces copays, not full retail prices.

What is the difference between Mounjaro and Zepbound? Both contain tirzepatide at identical doses. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. The active ingredient, mechanism, and side effect profile are the same. The only difference is the FDA indication and insurance coverage rules.

How much does Mounjaro cost without insurance? Approximately $1,050 to $1,200 per month for a 4-pen carton (one month supply) at retail pharmacies. Prices vary slightly by pharmacy. Compounded tirzepatide costs $250 to $400 per month and is the most common alternative for uninsured or denied patients.

Can I switch from brand Mounjaro to compounded tirzepatide? Yes, with provider supervision. Compounded tirzepatide is the same active ingredient. Most patients switch without issue, though some need dose adjustments due to potency variation between compounded batches. Work with a provider experienced in compounded GLP-1 management.

Will CVS Caremark cover Mounjaro if I gain weight while on it? Coverage is based on FDA indication, not outcomes. If you have type 2 diabetes and meet prior authorization criteria, Mounjaro remains covered regardless of whether you lose or gain weight. If you are using it off-label for weight loss, it is not covered regardless of outcomes.

What should I do if my CVS Caremark plan excludes Zepbound entirely? You have three options: (1) appeal to your employer's HR benefits team to add Zepbound to the formulary for the next plan year, (2) switch to compounded tirzepatide at $250 to $400 per month, or (3) try an alternative like Wegovy (semaglutide) if it is on your formulary.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
2. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Pharmaceutical Care Management Association. Prior Authorization Trends in Specialty Medications. 2025.
6. MMIT Formulary Insights. GLP-1 Receptor Agonist Coverage Trends Q1 2026. 2026.
7. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determinations and Appeals. 2024.
8. Social Security Act, Section 1862(a)(1)(A). Exclusions from Coverage and Medicare as Secondary Payer.
9. American Medical Association. AMA Adopts New Policies on Second Day of Voting at Annual Meeting. 2013.
10. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2024.
11. United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. 2023.
12. Eli Lilly and Company. Mounjaro Prescribing Information. 2024.
13. Eli Lilly and Company. Zepbound Prescribing Information. 2023.
14. CVS Caremark. Prior Authorization Criteria: Incretin Mimetics. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk. CVS Caremark is a registered trademark of CVS Health. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.